Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia/lymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zdiagnozowana białaczka lub chłoniak B-komórkowy, który powrócił lub nie reaguje na leczenie, oraz otrzymanie komercyjnego produktu terapii CAR T
- •Od 28 do 56 dni od infuzji terapii CAR T
- •Wiek co najmniej 18 lat
- •Zdolność połykania tabletek
- •Liczba granulocytów co najmniej 750/mm³
- •Liczba płytek krwi co najmniej 50 000/mm³
- •Prawidłowe funkcje wątroby i nerek
- •Kobiety mogące zajść w ciążę i mężczyźni muszą zgodnie uczestniczyć w programie bezpieczeństwa pomalidomide
✗ Disqualifies
- •Choroba postępująca lub niereagująca na leczenie CAR T
- •Aktywna choroba przeszczepu przeciwko gospodarzowi (GVHD) stopnia 2 lub wyższego
- •Aktywny zespół uwalniania cytokin (CRS) stopnia 2 lub wyższego
- •Aktywna neurotoksyczność związana z terapią CAR T (ICANS) stopnia 2 lub wyższego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Michigan Rogel Cancer Center
Ann Arbor, United States
Trial contact
Jennifer E Agrusa, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.